PNC Financial Services Group
MLYS icon

PNC Financial Services Group’s Mineralys Therapeutics MLYS Stock Holding History

PNC Financial Services Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.3K Hold
2,234
– – ﹤0.01% 3240
2026
Q1 		$60.5K Hold
2,234
– – ﹤0.01% 3114
2025
Q4 		$81.1K Hold
2,234
– – ﹤0.01% 2937
2025
Q3 		$84.7K Hold
2,234
– – ﹤0.01% 2914
2025
Q2 		$30.2K Buy
2,234
+28
+1% +$406 ﹤0.01% 3369
2025
Q1 		$35K Buy
2,206
+21
+1% +$242 ﹤0.01% 3284
2024
Q4 		$26.9K Sell
2,185
-26
-1% -$340 ﹤0.01% 3395
2024
Q3 		$26.8K Hold
2,211
– – ﹤0.01% 3377
2024
Q2 		$25.9K Hold
2,211
– – ﹤0.01% 3353
2024
Q1 		$28.5K Sell
2,211
-1,911
-46% -$23.6K ﹤0.01% 3260
2023
Q4 		$35.4K Buy
4,122
+4,099
+17,822% +$32.2K ﹤0.01% 3136
2023
Q3 		$219 Buy
+23
New +$300 ﹤0.01% 4529

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

PNC Financial Services Group's MLYS Position: Q2 2026 in Review

PNC Financial Services Group held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 2,234 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

PNC Financial Services Group first reported a position in MLYS in Q3 2023 and has held it in 12 quarters since. The position peaked at $84.7K in Q3 2025. 64 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • PNC Financial Services Group held 2,234 shares of Mineralys Therapeutics worth $60.3K as of Q2 2026.
  • PNC Financial Services Group left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3240 holding.
  • PNC Financial Services Group first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • PNC Financial Services Group's Mineralys Therapeutics position peaked at $84.7K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.